Brendan Carr Podcast | 20 September 2018 | 0h 28m | Listen Later | iTunes
Interview with Erik Brynjolfsson about his book, The Second Machine Age: Work, Progress, and Prosperity in a Time of Brilliant Technologies, co-authored with Andrew McAfee. Explains how to manage risk, why we can’t freeze the past and must embrace the future, and how to use advancing technologies to meet our goals.
Cautionary Tales | 19 June 2020 | 0h 24m | Listen Later | iTunes
Tim Harford uses the example of the Fukushima nuclear disaster to highlight the pitfalls of ignoring longer-term ills when taking action against urgent dangers.
How To Academy | 14 April 2020 | 1h 02m | Listen Later | iTunes
Interview with Mervyn King and John Kay about their book Radical Uncertainty: Decision-Making Beyond the Numbers. Highlights the successful – and the short-sighted – methods of dealing with an unknowable future. Argues that much economic advice is bogus quantification, with invented numbers offering false security; rather than robust narratives that yield the confidence to manage uncertainty.
The Knowledge Project with Shane Parrish | 14 April 2020 | 1h 04m | Listen Later | iTunes
Interview with angel investor Jason Calacanis discussing high stakes poker, how to make intelligent investing decisions, how systems enable or forbid, and demystifying the culture of Silicon Valley.
Masters in Business | 19 July 2019 | 1h 13m | Listen Later | iTunes
Interview with Allison Schrager, economist, writer and co-founder of the risk advisory firm Lifecycle Finance Partners LLC. Discusses her book An Economist Walks into a Brothel: And Other Unexpected Places to Understand Risk. Insightful perspectives on risk.
EconTalk | 9 November 2015 | 1h 10m | Listen Later | iTunes
Should women get routine mammograms? Should men get regular PSA exams? Interview with Robert Aronowitz, author of Risky Medicine, about the increasing focus on risk reduction rather than health itself as a goal. Discusses the social and political forces that push us toward more preventive testing even when those tests have not been shown to be effective. A provocative look at the opportunity cost of risk-reduction.